The laureates of the Charcot Fund 2018
The laureates of the Charcot Fund 2018 are known: a choice for concrete results, a focus on progressive MS and, as usual, support for innovative basic research.
FIGHTing MS THROUGH RESEARCH
The laureates of the Charcot Fund 2018 are known: a choice for concrete results, a focus on progressive MS and, as usual, support for innovative basic research.
As an encouragement for the groundbreaking work provided by our researchers, the Fondation Charcot Stichting will increase its financial support in 2018 from 200,000 euros to 300,000 euros. Discover our Newsletter.
Great progress has been made in 30 years! We can now establish a diagnosis much faster and we can implement increasingly effective early treatment...
It illustrates the complexity and time it takes to complete innovative work, the development of new technical tools, the creation of new therapeutic concepts, feasibility tests using experimental animal models, and, finally the “full scale” trials on people and human diseases. Piet Stinissen quite rightly reminds us that some new treatments of MS use monoclonal antibodies, whose discovery dates back to 1975, and which earned Köhler and Milstein the Nobel Prize in Medicine.
Vitamin D deficiency is frequent in Northern Europe as 90% of Vitamin D is synthesized in the skin under the effect of the sun’s ultraviolet irradiation. Low Vitamin D blood levels in childhood and adolescence are a factor in the development of multiple sclerosis in adulthood. In a Finnish study published in March 2016, mothers with inadequate Vitamin D levels in early pregnancy almost doubled the risk of their children developing multiple sclerosis.
